Abbisko Cayman Limited (SEHK: 2256)
Health Care · Biotechnology · CN
HK$10.54
-2.59% today · -34.2% 1Y
Abbisko Cayman Limited (SEHK: 2256) operates in the Biotechnology industry within the Health Care sector. The company is valued at $962.29M and employs 276 people.
Over the last twelve months the share price has lost 34.2%, trading between 8.34 and 19.78.
Tweenvest scores Abbisko Cayman Limited across four factors: quality 57/100, value 23/100. Its strongest factor is quality.
2256 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $962.29M
- Revenue (TTM)
- $87.52M
- P/E
- 107.09
- EPS
- 0.09
- Dividend yield
- —
- Beta (5Y)
- 1.20
- 52-week high
- HK$19.78
- 52-week low
- HK$8.34
- Avg volume (3M)
- —
- Shares outstanding
- 716.46M
- Employees
- 276
- Next earnings
- —
About Abbisko Cayman Limited
Founded in 2016 and headquartered in Shanghai, People's Republic of China, Abbisko Cayman Limited operates as a clinical-stage biopharmaceutical company. Its core mission involves the discovery and advancement of small molecule oncology therapeutics. The company's development efforts primarily target small molecule precision oncology and immuno-oncology therapeutic areas. Among its prominent product candidates are ABSK011, a small molecule designed to inhibit fibroblast growth factor receptor 4, intended for advanced hepatocellular carcinoma characterized by hyper-activation of FGF19/FGFR4 signaling. Another significant asset is ABSK091, a molecularly targeted candidate addressing a range of solid tumors, including urothelial, gastric, cholangiocarcinoma, and lung cancers. Furthermore, Abbisko Cayman Limited maintains a broader pipeline of other promising product candidates.
- ISIN
- KYG0028A1085
- Founded
- 2016
- Listed since
- Oct 13, 2021
- Exchange
- The Stock Exchange of Hong Kong Ltd.
- Currency
- HKD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $264.52 | -0.17% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $443.84 | +1.03% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $146.74 | +0.42% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $547.59 | -0.08% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $828.50 | -0.66% |
| argenx SEENXTBR: ARGX | $63.06B | €874.20 | +1.16% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $142.94 | +2.92% |
Figures last refreshed Aug 18, 2026.